PTO/SB:08A (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

equired to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number
Filing Date
First Named Inventor

(use as many sheets as necessary)

Sheet

of

 Complete if Known

 Application Number
 10/088,952
 RECEIVED

 Filing Date
 March 22, 2002
 RECEIVED

 First Named Inventor
 Leppla, Stephen
 DEC 3 + 1

 Art Uni
 Not yet assigned
 DEC 3 + 1

 Examiner Name
 Not yet assigned
 FCH CENTER

 Attorney Docket Number
 12880-405100US
 FCH CENTER

	U.S. PATENT DOCUMENTS					
Examiner	Cite No 1	Document Number  Number Kind Code <sup>2</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cried Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AA	US-5,677,274	10/14/97	Leppla et al	Figures Appear	
	AB	US-5,817,771	10/06/98	Hagen et al		
	AC	US-				
	AD	US-				
	AE	US-				
	AF	US-				
	AG	US-				
	AH	US-				
	Al	US-				
	AJ	US-				
	AK	US-				
	AL	US-				
	AM	US-				
	AN	US-				
	AO	US-				
	AP	US-				
	AQ	US-				
	AR	US-				
	AS	US-				
	A.T	119				

FOREIGN PATENT DOCUMENTS								
Examiner Initials'	Cite No	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,		
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if Anown)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	AU							
	AV							
	AW							
	AX							
	AY							
	AZ							
	BA							
	BB							

Examiner Signature Date Considered		

EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique station designation number (optional). \*Kind Codes of U.S. Patient Documents at your <u>station go</u>r of MDEP 90.1 04. \*Enter Office that store the document, by the two-letter code (VMC) Standard \$13], \*For planning expland documents, the indication of the year of the representation of the company of the Emperor must precide the serial number of the flatent document. \*Hond of document by the appropriate symbols as indicated on the document under VMDO Standard \$13 in a florestiff - Applicant to store a check mark there of English Inauguent Transitions is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete his form should be sent to the Chef Information Officer, U.S. Patient and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

DEC 2 6 2002 5	App U.S. Patent and Trade sare required to respond to a collection of			
Substitute for form 144		Complete if Known		١
	Application Number	10/088,952		
INFORMATION DISCLOSURE	Filing Date	March 22, 2002		L
STATEMENT BY APPLICANT	First Named Inventor	Leppla, Stephen	REC	EIVED
	Art Unit	Not yet assigned	DEC.	
(use as many sheets as necessary)	Examiner Name	Not yet assigned	DEC :	1 2002

Attorney Docket Number

015280-405100US

CENTER 1600/2900

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T ²				
	ВС	LIAW, L and CRAWFORD, H C, "Functions of the extracellular matrix and matrix degrading proteases during tumor progression" Braz. J. of Med. and Biol. Res. (1999) 32:805-812					
	BD	MAZAR, A P and JONES, T R., Abstract, XP-002131000, #146 "High-affinity, small cyclic peptide urokinase plasminogen activator receptor (uPAR)-largeting igands localize recorder and therapeutic conjugates to the surfaces of tumor cells and simulated endothelial colls," Angst Phar. 1,999					
	BE						
	BF						
	BG						
	вн						
	Bi						
	BJ						
	ВК						
	BL						
	ВМ						

Examiner Signature	/Brandon Fetterolf/	Date Considered	06/26/2008
Signature	1	Considered	

ExAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

2

Sheet

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chef Information Officer, U.S. Patent and Trademark. Office: Washington, C.O. 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, D.C. 20231

SET 1416157.7